Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer
Adam Brufsky, Rachel M Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron Cohen, Melissa Estevez, Paul Cottu, Marc Thill, Giuseppe Curigliano, Hope S Rugo · 2026
Read Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer by Adam Brufsky, Rachel M Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron Cohen, Melissa Estevez, Paul Cottu, Marc Thill, Giuseppe Curigliano, Hope S Rugo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13228134.txt.
Description
Three drugs of the CDK4/6 class anchor first-line care for a common hormone-driven breast cancer that has spread. The authors of this 2026 study mined United States health records to compare how long patients stay on each drug and what comes next.
The records covered 11,557 people starting one of the three drugs with a hormone blocker. After weighting to balance the groups, palbociclib lasted longest, with a median near twenty-one months, ahead of the other two. Stopping rates at one year were also lowest for that drug. Later care often kept a drug from the same class, and switches toward palbociclib were the most common.
Catalog record
| CREATOR | Adam Brufsky, Rachel M Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron Cohen, Melissa Estevez, Paul Cottu, Marc Thill, Giuseppe Curigliano, Hope S Rugo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |